A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout


This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.

Full Title of Study: “A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2012


  • Drug: febuxostat
    • oral
  • Drug: Allopurinol
    • oral

Arms, Groups and Cohorts

  • Experimental: febuxostat group
    • oral
  • Active Comparator: allopurinol group
    • oral

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of subjects whose serum urate level decreases to < 6.0 mg/dL
    • Time Frame: week 12

Secondary Measures

  • Percent reduction in serum urate levels
    • Time Frame: Baseline and at week 12
  • Safety assessed by the incidence of adverse events, physical exam. and vital signs, tabo-tests and 12-lead ECG
    • Time Frame: Baseline and at week 12

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects will also have a history or presence of gout as defined by the American College of Rheumatology (ACR) criteria – Subject has serum urate level >= 8.0 mg/dL at the screening Visit Exclusion Criteria:

  • Female subject who is breast-feeding or pregnant – Subject has a history of xanthinuria – Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson syndrome/topic epidermal necrolysis – Subject who takes allopurinol > 300 mg/day and with serum urate level > 8mg/dL – Subject who is HLA B*5801 positive – Subject who is receiving thiazide diuretic therapy – Subject who has secondary hyperuricemia – Subject who requires concurrent therapy with any systemic or topical medications, prescribed or non-prescribed, containing aspirin or other salicylates (low doses of aspirin will be allowed(ie. =< 325mg/day) – Subject who requires therapy with prednisone > 10 mg/ day during the study – Subject who has active liver disease or hepatic dysfunction, defined as both ALT and AST > 1.5 times the upper limit of normal – Subject who has serum creatinine >= 1.5mg/dL – Subject who has any another significant medical condition as defined by the investigator that would interfere with the treatment, safety or compliance with the protocol (eg. A clinically significant ECG result) – Subject who has a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the study, or has taken any systemic cancer chemotherapy within 5 years prior to the study – Subject who has previously participated in a clinical study in which febuxostat was administered – Subject who has participated in another investigational trial within the 30 days prior to the study

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Astellas Pharma Taiwan, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Director, Study Director, Astellas Pharma Taiwan, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.